<div id="readability-page-1"><p>Turn Therapeutics Inc. (NASDAQ:TTRX - Get Free Report) Director Arthur Golden bought 9,868 shares of Turn Therapeutics stock in a transaction dated Monday, November 24th. The stock was purchased at an average cost of $3.44 per share, for a total transaction of $33,945.92. Following the completion of the acquisition, the director directly owned 60,602 shares of the company's stock, valued at approximately $208,470.88. The trade was a 19.45% increase in their position. The transaction was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through this hyperlink.</p><div><p><span></span><span>Get <strong>Turn Therapeutics</strong> alerts:</span></p></div><h2>Turn Therapeutics Price Performance</h2><p>Shares of TTRX stock traded down $0.20 on Tuesday, reaching $3.30. The company's stock had a trading volume of 82,657 shares, compared to its average volume of 109,339. Turn Therapeutics Inc. has a 1 year low of $2.57 and a 1 year high of $26.50. </p><p>Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) EPS for the quarter. </p><h2>Turn Therapeutics Company Profile</h2> (Get Free Report)<p>We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Turn Therapeutics</li><li>What Are Dividend Contenders? Investing in Dividend Contenders</li><li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li><li>What is the S&amp;P 500 and How It is Distinct from Other Indexes</li><li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li><li>Breakout Stocks: What They Are and How to Identify Them</li><li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Turn Therapeutics Right Now?</h2><p>Before you consider Turn Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.</p><p>While Turn Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TTRX

<p>Turn Therapeutics Director Arthur Golden purchased 9,868 shares, increasing his ownership by 19.45%. The transaction, valued at $33,945.92, was disclosed in an SEC filing. The stock price decreased by $0.20 to $3.30, with a trading volume of 82,657 shares. Turn Therapeutics reported a quarterly EPS of ($0.07).</p>

Turn Therapeutics (NASDAQ:TTRX) Director Purchases $33,945.92 in Stock